COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways plc (NASDAQ:CMPS) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 5,440,000 shares, a growth of 21.7% from the January 31st total of 4,470,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 5.3 days.

COMPASS Pathways Stock Performance

NASDAQ CMPS opened at $4.04 on Thursday. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $4.05 and a 200-day moving average price of $5.18. COMPASS Pathways has a twelve month low of $3.17 and a twelve month high of $11.72. The firm has a market cap of $276.42 million, a price-to-earnings ratio of -1.84 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, equities research analysts predict that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

A number of institutional investors have recently modified their holdings of CMPS. China Universal Asset Management Co. Ltd. purchased a new stake in COMPASS Pathways in the fourth quarter worth about $41,000. Wealthfront Advisers LLC purchased a new stake in COMPASS Pathways during the fourth quarter worth $43,000. Flagship Harbor Advisors LLC purchased a new stake in COMPASS Pathways during the fourth quarter worth $43,000. Conservest Capital Advisors Inc. lifted its holdings in COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after buying an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth $54,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CMPS shares. Canaccord Genuity Group dropped their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.